Growth Metrics

BioNTech SE (BNTX) Income from Non-Controlling Interests (2018 - 2019)

BioNTech SE (BNTX) posted Income from Non-Controlling Interests of $17710.2 for Q4 2019, down 87.26% on a QoQ basis from $138973.0 in Q4 2018, and down 87.26% year-over-year from $138973.0 in Q4 2018.

BioNTech SE (BNTX) has 2 years of Income from Non-Controlling Interests data on file, last reported at $17710.2 in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -13.75 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 BioNTech SE 27.66 Bn 7.53 Bn 668.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 17,710.20
Dec 31, 2018 138,973.00
Sep 30, 2018 -54,667.07